Anti-KIDINS220 antibody produced in rabbit

KIDINS220 (kinase D-interacting substrate, 220kDa) is a newly discovered protein, which has a predominant expression in the developing nervous system. This gene is localized to human chromosome 2q. The encoded protein is of 22kDa, and is composed of three functional domains. One domain acts as a scaffold for MAPK/ERK (extracellular signal-regulated kinase (ERK) kinase) signaling cascade, and also interacts with Trk, Eph, and VEGF (vascular endothelial growth factor). It has a kinesin binding domain, which also interacts with microtubule associated proteins (MAPs). The last domain is an ankyrin rich domain, present in the N-terminal and interacts with Trio, which is a RhoGEF. It has four transmembrane regions, and both N- and C-termini face the cytoplasm.

Ankyrin repeat-rich membrane spanning protein recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

KIDINS220 (kinase D-interacting substrate, 220kDa) is a ligand for tyrosine kinase receptors in neurons. It plays an essential role in the development and survival of neurons, by mediating neurotrophic signaling. It is expressed in neuroblastoma and facilitates neuroblastoma cell survival, through nerve growth factor (NGF)-mediated signaling. In neural crest tumors, it is responsible for the neuroblastic (N-type) cell to Schwannian stromal (S-type) cell transition. It is also up-regulated in melanoma, and facilitates melanoma migration and invasiveness via, extracellular signal-regulated kinase (ERK) (MEK)/ERK signaling pathway. It is hypothesized that KIDINS220 plays a role in regulating cytoskeleton dynamics, thus affecting cell movement in both pathological and normal conditions. Excitotoxicity and cerebral ischaemia lead to suppression of this protein, which results in neuronal death. In Alzheimer′s disease (AD), KIDINS220 accumulates along with tau protein, due to resistance to calpain processing. Thus, it has potential as a therapeutic target in AD.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Corresponding Antigen APREST73113

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany